Markets remain shaky this week, and CNBC "Fast Money" traders looked for stocks that provide long-term stability.» Read More
Big tech names such as Facebook and Google have excelled this year, but one trader says the large cap tech ETF is a risky buy.
Sept 14- Raptor Pharmaceutical Corp said it did not plan to develop its liver drug after it failed to meet the main goal in a second mid-stage study, wiping out more than a third of the company's market value. The drug, RP103, was being tested in children with nonalcoholic steatohepatitis, which is characterized by fat buildup in the liver, along with inflammation...
Pros pick top small, mid and large cap stocks
The high-grade bond market is springing back to life as corporations race to issue new debt and get out in front of a possible Fed interest rate hike.
Sept 2- Gilead Sciences Inc said on Wednesday its experimental fixed-dose combination treatment for HIV proved as effective in a late-stage study as the company's widely used Truvada combo pill but with significantly less loss of bone mineral density and kidney function. Gilead shares were up 0.5 percent to $101.95 in morning trading on the Nasdaq, versus a...
Sept 1- Gilead Sciences Inc said on Wednesday its experimental fixed-dose combination treatment for HIV proved as effective in a late-stage study as the company's widely used Truvada combo pill but with significantly less loss of bone mineral density and kidney function. Gilead shares were up 1.6 percent to $102.88 in morning trading on the Nasdaq,...
Experienced investors use China-driven market selloffs to buy these quality companies.
Nearly 400 members of the S&P 500 were "oversold" on a statistical basis at the end of last week and therefore should rebound this week.
The healthcare secular theme isn't new, but is still very much in force.
For this market to truly find a bottom, China needs to do more and the Fed needs to do less, says Ron Insana.
No matter what happens to the markets on Monday, there's going to be a lot of action in Apple either way.
Data from Axioma show that the most concentrated risk in the Nasdaq 100 is confined to the top six stocks.
Despite muted returns for the S&P 500 in 2015, analysts on Wall Street just love these stocks.
July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...
U.S. stocks closed higher after the Fed kept rates unchanged and the continued recovery in oil prices encouraged investor sentiment.
*Fed statement expected at 2 p.m. ET. *Yelp falls sharply after revenue misses expectations. The statement is expected at 2 p.m. ET.
Some of the names on the move ahead of the open.
July 29- U.S. stock index futures rose on Wednesday on hopes that Beijing could stem the rout in its markets and ahead of a statement from the U.S. *In a recent congressional testimony, Fed Chair Janet Yellen neither ruled out a September interest rate hike nor guided the market toward thinking it was a done deal. The statement is expected at 2 p.m. ET.
July 28- Gilead Sciences Inc said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers. Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street...
The "Fast Money" traders awarded their final grades to the Gilead, Twitter and Yelp following their quarterly earnings reports.